108 results about "Tissue inflammation" patented technology

The invention relates to the technical field of biological medicines, in particular to rhizoma drynariae extracellular vesicles for treating periodontitis by targeting macrophage ETS2 genes as well as a preparation method and application of the rhizoma drynariae extracellular vesicles. The extracellular vesicles are creatively extracted from the traditional Chinese medicine rhizoma drynariae by combining a differential ultracentrifugation method with a sucrose density gradient centrifugation method, the functions of the extracellular vesicles are studied, and it is found that the extracellular vesicles can effectively slow down alveolar bone resorption in a periodontitis state and reduce periodontal soft tissue inflammation and have a good treatment effect on periodontitis. It is found for the first time that the rhizoma drynariae extracellular vesicles can reduce the inflammatory ability of macrophages in an inflammatory state and can reduce expression of proinflammatory factors TNF-alpha and IL-6. The invention has important scientific research value and clinical significance for further development and application of various traditional Chinese medicine plant extracellular vesicles including rhizoma drynariae extracellular vesicles.

Embodiments treat inflammation of a user by applying a first patch on a dermis of the user adjacent to an afferent nerve, the first patch comprising first electrodes, and applying a second patch on the dermis of the user adjacent to a vagus nerve or a vagus nerve connecting branch, the second patch comprising second electrodes. Embodiments generate a treatment protocol during a time period comprising simultaneously applying a first electrical stimuli to the afferent nerve via the first electrodes of the first patch and applying a second electrical stimuli to the vagus nerve or the vagus nerve connecting branch via the second electrodes of the second patch.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The utility model discloses a poly (p-dioxanone) medical suture with an anti-inflammation capsule, and relates to the technical field of medical sutures. The protein anti-inflammatory suture line comprises a suture line inner core, a protein adhesive layer, a protein microcapsule and anti-inflammatory drug particles, wherein the suture line inner core is made of a PPDO material. According to the utility model, the anti-inflammatory drug of the wound can be fully and comprehensively absorbed; the inner core of the suture line has good compatibility, and rejection and tissue inflammation are reduced; the suture line can be gradually degraded in the body and finally converted into carbon dioxide, water and the like, and the carbon dioxide, the water and the like are naturally discharged by the human body and do not need to be removed through a secondary operation, so that the infection risk possibly caused by the secondary operation is reduced, and the infection risk is reduced; the suture line has long strength maintenance time and can provide continuous support for the wound until the tissue is healed; the protein microcapsules and the anti-inflammatory drug particles are beneficial to reducing inflammatory reaction.

The invention discloses a histone-derived peptide nano-particle for targeted degradation of cytoplasm cGAS and a preparation method and application thereof, and is characterized in that a polypeptide compound is dissolved in a phosphate buffer, ultrasonic treatment and room temperature standing self-assembly are performed to form nano-particles, and centrifugal purification is performed to obtain the histone-derived peptide nano-particle A4-CMA NPs for targeted degradation of cytoplasm cGAS. The nano-particles (A4 at CMA NPs) can be combined with cytoplasm cGAS in a targeted manner and mediate the cytoplasm cGAS to degrade, so that the activation of a cGAS-STING pathway is blocked, periodontal tissue inflammation and alveolar bone resorption are effectively relieved, and a new strategy is provided for periodontitis treatment.

The application relates to the field of high polymer materials, in particular to an exosome composite material for treating periodontitis and a preparation method thereof. The exosome composite material comprises the following raw materials in parts by weight: 10-20 parts of a chitosan derivative, 10-20 parts of sodium hyaluronate, 1-5 parts of zein, 0.5-1 part of exosomes, 0.1-0.3 parts of phosphonodipeptide sodium and 60-70 parts of deionized water. The exosome composite material can inhibit periodontal pathogenic bacteria, reduce the expression of proinflammatory factors by inhibiting the signal pathways such as NF-kappa B, and thus relieve periodontal tissue inflammation.

The invention discloses a periodontitis marker and application thereof. Belongs to the technical field of biomedical detection. Experiments prove that the expression of the hsacirc0005737 in patient tissues, periodontal ligament stem cells in an inflammation microenvironment and periodontitis model mouse tissues is remarkably up-regulated, and the expression level of the hsacirc0005737 is positively correlated with the severity and activity of periodontitis. Therefore, detection of the expression level can be used for diagnosis, activity evaluation, curative effect monitoring and prognosis of periodontitis. In addition, the osteogenic differentiation capacity and inflammatory response of the periodontal ligament stem cells can be influenced by regulating the expression of the hsacirc0005737, so that the hsacirc0005737 can be used as a potential target for treating periodontitis. The invention further provides a primer sequence, a detection reagent combination and a kit for detecting the hsacirc0005737, and a new solution is provided for noninvasive, early-stage and high-specificity diagnosis and targeted therapy of periodontitis.

The invention relates to an intestinal tissue inflammation injury treatment target spot and application thereof, and belongs to the technical field of biological medicine. It is found that the level of DPF2 in intestinal tissue inflammation damage can significantly affect regeneration and repair of intestinal tissue, high-level DPF2 can promote intestinal tissue inflammation damage, and after the DPF2 gene is knocked out, intestinal tissue inflammation damage can be significantly reduced. Clinical intestinal tissues are subjected to DPF2 immunostaining, clinical cases are divided into a high-inflammation injury group and a low-inflammation injury group, the high-inflammation injury group shows a higher DPF2 level, it is indicated that DPF2 can indeed serve as a new index for evaluating and diagnosing intestinal tissue inflammation injury, and the DPF2 has a good clinical application prospect.

This invention discloses a histone-derived peptide nanoparticle targeting the degradation of cytoplasmic cGAS, its preparation method, and its applications. The invention is characterized by: dissolving a peptide complex in phosphate buffer, sonicating, allowing it to self-assemble at room temperature to form nanoparticles, and purifying by centrifugation to obtain histone-derived peptide nanoparticles A4@CMA NPs targeting the degradation of cytoplasmic cGAS. These nanoparticles (A4@CMA NPs) can target and bind to cytoplasmic cGAS, mediating its degradation, blocking the activation of the cGAS-STING pathway, effectively reducing periodontal inflammation and alveolar bone resorption, and providing a new strategy for the treatment of periodontitis.

The invention discloses a traditional Chinese medicine composition for treating allergic asthma and a preparation method thereof, and the traditional Chinese medicine composition comprises the following components in parts by weight: 2-10 parts of honey-fried ephedra, 3-10 parts of scutellaria baicalensis, 9-15 parts of momordica grosvenori, 9-15 parts of rhizoma dioscoreae nipponicae, 5-10 parts of scalded semen armeniacae amarae, 2-10 parts of liquorice, 3-10 parts of fried fructus perillae, 3-9 parts of fried semen brassicae, 5-10 parts of schizonepeta, 3-10 parts of platycodon grandiflorum and 5-12 parts of fried semen raphani. The pharmaceutical composition disclosed by the invention is a pure traditional Chinese medicine preparation, and can be used for reducing the level of eosinophilic granulocytes, increasing the number of alveolar macrophages and effectively improving abnormal immune response in an asthma process; lesion degrees such as lung tissue inflammatory cell infiltration, alveolar wall edema and goblet cell hyperplasia are relieved; secretion of Th2 type inflammatory cell related factors and IgE is reduced, and finally the effect of treating allergic asthma inflammatory response is achieved.

The present invention discloses a coumarin HDAC6 inhibitor and its preparation method and application, belonging to the field of chemical medicine technology. The present invention provides coumarin compounds shown in Formula I, Formula II and Formula III. Based on the structure of coumarin, the characteristic group of HDAC6 inhibitor hydroxamic acid is introduced to achieve good homologous selectivity for HDAC1 / 6; at the enzyme level, cell level and animal experiment level, it is verified that the compound has excellent target inhibition effect; by studying the example of HDAC6-NF-κB participating in the inflammatory response of colonic tissue, a new practical basis is provided for the treatment of ulcerative colitis. The compound provided by the present invention can be used as a new HDAC6 inhibitor to prevent and treat HDAC6-related diseases, especially it is expected to solve the shortcomings of some current small molecule drugs for the treatment of ulcerative colitis, such as poor relief effect and large side effects.

Disclosed are methods, systems, media, apparatus, devices, and other implementations, including a method that includes determining blood flow characteristics at an ocular surface of an eye of a patient, determining characteristics of blood vessels at the ocular surface of the eye based on the determined blood flow characteristics, and deriving one or more ocular redness grading scales indicative of inflammation levels of the eye of the patient based on the determined characteristics of the blood vessels at the ocular surface of the eye.

The present application relates to the technical field of medical devices, and particularly relates to a controlled release device, a preparation method thereof and an intelligent microneedle closed loop system. The controlled release device comprises a metal microneedle, a doped polypyrrole film coated on the surface of the metal microneedle and a drug loaded on the doped polypyrrole film. The controlled release device realizes the electrically controlled on-demand release of hypoglycemic drugs, and can make metformin release 41.1 mu g in 400 minutes, thereby providing a new possibility for personalized treatment of diabetes. Meanwhile, the present application also constructs an intelligent microneedle closed loop system by using a microneedle sensor, realizes real-time monitoring of blood glucose and linkage control of on-demand drug delivery, and can be continuously worn for seven days without tissue inflammation.

The main purpose set by the present inventors is to provide a technology for suppressing inflammation particularly in aged tissue in the oral cavity.　The present inventors have discovered that it is possible to suppress inflammation particularly in aged tissue in the oral cavity by an oral cavity composition that contains β-glycyrrhetinic acid and at least one selected from the group consisting of retinol acetate, retinol, all-trans-retinoic acid, ascorbic acid, cobalamin, calciferol, anthraquinone, L-histidine, methylhesperidin, and chemically possible salts thereof.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

The invention discloses a traditional Chinese medicine composition for treating cerebral infarction. The composition is prepared from the following raw materials in parts by weight: 15-25 parts of arisaema cum bile, 15-25 parts of bulbus fritillariae thunbergii, 10-20 parts of rhizoma gastrodiae, 10-15 parts of rhizoma atractylodis macrocephalae, 10-15 parts of radix paeoniae alba, 15-20 parts of ligusticum wallichii, 15-20 parts of caulis spatholobi, 20-30 parts of herba lycopi, 10-15 parts of coptis chinensis, 10-15 parts of rhizoma acori graminei, 10-20 parts of ginseng and 5-10 parts of lumbricus. The traditional Chinese medicine composition is reasonable in compatibility according to etiology and pathogenesis of cerebral infarction, all the medicines jointly achieve the effects of promoting blood circulation, removing blood stasis, descending turbidity, extinguishing wind, eliminating phlegm and dredging collaterals, cerebral tissue infarction and neurological function impairment can be obviously improved, and the action mechanism of the traditional Chinese medicine composition is related to cerebral tissue inflammatory response relieving, oxidative stress inhibiting and the like.

The invention provides a construction method and application of a chicken fallopian tube embolism model, and belongs to the technical field of animal infection models. The invention provides a construction method of a chicken fallopian tube embolism model based on multi-pathogen infection. The mycoplasma synoviae, the infectious bronchitis virus and the riemerella anatipestifer are utilized to infect the chicken, and the clinical typical salpingemphasis pathological process including cheese-like substance accumulation in a salpingemphasis cavity, serious abdominal air sacculitis complications and related tissue inflammation changes can be accurately reproduced. The model constructed by the invention is high in morbidity, and is suitable for epidemic disease pathogenesis research, drug screening and vaccine potency test. Compared with an existing single pathogen infection model, the model is closer to a clinical reality multi-pathogen cooperative infection scene, and the blank of a standardized multi-pathogen mixed infection induced fallopian tube embolism animal model is filled up.

The application belongs to the technical field of biological medicine, and particularly relates to application of calcium chelator BAPTA and a pharmaceutical composition. The calcium chelator BAPTA delays aging of lung fibroblasts and lung tissues by eliminating calcium accumulation in lung fibroblasts, reducing accumulation of reactive oxygen species ROS (ROS) in lung fibroblasts, DNA damage, and release of inflammatory factors. The calcium chelator BAPTA ultimately realizes the function of treating pulmonary fibrosis by inhibiting weight loss, lung tissue inflammatory cell infiltration, lung collagen deposition, and expression of fibrosis markers. The application provides a new drug source for delaying aging of lung fibroblasts and lung tissues and studying occurrence and development of pulmonary fibrosis. The drug is safe and reliable, has strong pharmacological action, small side effects, and definite curative effect.

A method of treating an inflammatory condition in mucosal tissue of the airways of a subject, the method comprising locally contacting mucosal airway tissue of the subject with a microemulsion comprising a cannabinoid compound, and wherein the microemulsion when in a diluted form has a viscosity of 15cP or less, a surface tension of 45 mN / m or less and a hydrodynamic radius of 100 nm or less. Also a kit for treating an inflammatory condition in mucosal tissue of the airways in a subject, comprising (a) the microemulsion comprising the cannabinoid; and (b) a device for delivering the microemulsion to the mucosal tissue of the airways of the subject, wherein the device delivers the microemulsion in a liquid, spray, or aerosolized form.

The composition provided by the invention takes bear gall wood as a monarch drug and takes earthworm, bletilla striata, bighead atractylodes rhizome, Chinese yam and white paeony root as ministerial drugs, the earthworm and bletilla striata jointly play the effects of promoting blood circulation to remove meridian obstruction, dispersing blood stasis, removing stasis, astringing to stop bleeding and repairing injury, and the bighead atractylodes rhizome and Chinese yam are used as ministerial drugs and are used for strengthening spleen and stomach, replenishing qi and blood, providing fundamental power for the whole prescription and supporting healthy qi; liver softening, spasm relieving and pain relieving can be achieved; meanwhile, the traditional Chinese medicine composition has the effects of nourishing blood and astringing yin, can prevent other medicines in the formula from being too warm and dry or consuming yin blood, and forms dynamic and static combination compatibility with the minister medicine earthworm for promoting blood circulation to remove meridian obstruction; hairyvein agrimony, herba violae, vernonia graveolens, cuttlebone, mangnolia officinalis, semen raphani and endothelium corneum gigeriae A large number of pathological experiments prove that the traditional Chinese medicine composition can reduce stomach tissue inflammation, oxidative stress and activate apoptosis signal channels by acting on MAPK, PI3K-Akt and HIF-1 signals, so that the effect of treating chronic atrophic gastritis is achieved.

A system (100) for detecting tissue inflammation, gingivitis specifically, including a light emitter (102) configured to emit light at a tissue region within a user's mouth; at least four wavelength-sensitive photodetectors (110, 112, 114, and 116) configured to detect optical signals diffusely reflected through the tissue region, each of the at least four wavelength-sensitive photodetectors comprising a filter (BPF1, BPF2, BPF3, and BPF4) and a photodiode (D1, D2, D3, and D4), where the photodiodes are stacked on top of each other to generate current differential signals for amplifiers corresponding with the photodiodes, wherein the generation of the current differential signals removes an unwanted component from the optical signals prior to amplification; and an inflammation detection unit (136) configured to receive outputs from the corresponding amplifiers and detect inflammation at the tissue region.

The invention provides a traditional Chinese medicine composition for treating renal proteinuria as well as a preparation method and application thereof, and particularly belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30-60 parts of radix astragali, 10-20 parts of roasted rhizoma atractylodis macrocephalae, 8-16 parts of rhizoma polygoni cuspidati, 8-16 parts of rhizoma alismatis, 10-20 parts of rhizoma smilacis glabrae, 8-16 parts of rhizoma curcumae longae, 8-16 parts of lumbricus, 8-16 parts of silkworm larva, 10-20 parts of herba lysimachiae, 10-20 parts of herba centellae, 10-20 parts of sticktight and 10-20 parts of limonium bicolor. The traditional Chinese medicine composition can effectively relieve proteinuria, protect the renal function and regulate the expression of kidney inflammation macrophages, and particularly has the effects of promoting the expression of anti-inflammatory macrophages, reducing the inflammatory factor level of kidney tissue and inhibiting an inflammation signal channel. The traditional Chinese medicine composition provides a safe and effective medicine for treating proteinuria for patients.

The invention relates to the technical field of biological medicine, in particular to an efficient macrophage targeting vesicle system as well as a preparation method and application thereof. The vesicle system is a chimeric vesicle (mHEs), and is prepared from extracellular vesicles (M2-EVs) derived from M2 type macrophages and apoptotic small bodies (MSC-ABs) derived from bone marrow mesenchymal stem cells. The vesicle system provided by the invention can realize specific recognition and functional regulation of macrophages, thereby playing an efficient therapeutic role in pathological processes such as tissue inflammation repair, myocardial infarction, ischemia-reperfusion injury and immune metabolism remodeling.

The invention relates to a tissue state evaluation method and tissue elasticity detection device.The method comprises the steps that measurement data of to-be-detected tissue are obtained, and measurement parameters of the to-be-detected tissue are obtained through measurement of the tissue elasticity detection device and comprise elasticity detection parameters, blood flow detection parameters and / or ultrasonic detection parameters; determining comprehensive evaluation parameters according to the measurement data of the to-be-measured tissue; inputting the comprehensive evaluation parameters into a trained tissue inflammation degree evaluation model to obtain the inflammation degree of the to-be-tested tissue; the measurement data of the to-be-tested tissue and the inflammation degree of the to-be-tested tissue are input into a trained tissue state evaluation model, state information of the to-be-tested tissue is obtained, and the state information is one of a pathological change and a non-pathological change.

The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating hepatic fibrosis, aiming at solving the problems of insufficient curative effect specificity, liver and kidney toxicity and the like in the current treatment of hepatic fibrosis, the traditional Chinese medicine composition for treating hepatic fibrosis comprises the following components in parts by weight: 10 parts of astragalus membranaceus, 10 parts of rhizoma polygonati, 20 parts of mallotus root, 20 parts of turtle shell, 20 parts of salvia miltiorrhiza, 10 parts of codonopsis pilosula, 10 parts of prepared polygonum multiflorum, 13.2 parts of capillary artemisia, 10 parts of rhizoma sparganii, 10 parts of white paeony root and 10 parts of poria cocos. , 8 parts of radix curcumae, 4 parts of endothelium corneum gigeriae galli and 4 According to the traditional Chinese medicine composition disclosed by the invention, through reasonable compounding of the components and optimization of the dosage, the traditional Chinese medicine composition disclosed by the invention can be used for remarkably improving the weight gain and the liver-spleen index of a hepatic fibrosis model mouse, reducing the expression level of inflammatory factors and fibrosis indexes in hepatic tissues and serum, relieving hepatic tissue inflammation infiltration and collagen deposition, and improving the hepatic fibrosis rate. The curative effect on hepatic fibrosis is obvious, and liver and kidney toxicity is avoided.

The invention discloses an application of OTX008 in the treatment of HSV-1 virus infection. The application verifies that the galectin-1 selective inhibitor OTX008 can remarkably promote activation of an I-type interferon signal channel of a host after virus infection by constructing a mouse model infected by an HSV-1 virus; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows an immunopotentiation effect in mouse peritoneal macrophages. Therefore, the OTX008 disclosed by the invention can be used for promoting the function of an innate immune cell and inhibiting the replication of the HSV-1 virus in the cell; an immune escape strategy of the HSV-1 virus is cracked; the defect of high drug resistance of the traditional HSV-1 virus treatment drug is overcome to a certain extent; according to the application, a new host drug target spot is found, and a good clinical application prospect in resisting HSV-1 virus infection is shown.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to application of herba artemisiae scopariae and an ethanol herba artemisiae scopariae extract in a medicine for treating autoimmune hepatitis, the ethanol herba artemisiae scopariae extract can reduce ALT and AST of a patient suffering from the autoimmune hepatitis, can effectively reverse liver tissue lesions of the patient suffering from the autoimmune hepatitis, and has the advantages that the curative effect is good, and the curative effect is good. The content of collagen fibrinogen in animal livers is reduced, so that hepatic fibrosis of patients with the autoimmune hepatitis is effectively reversed, proinflammatory factors TNF-alpha, IL-6 and IL-1beta in serum are reduced, the content of an anti-inflammatory factor IL-10 is increased, and the composition has a protective effect on inflammatory injury of liver tissues with the autoimmune hepatitis and can be used for treating the liver with the autoimmune hepatitis. And the content of serum immune globulins IgG and IgM can also be reduced. Through the effects, the oriental wormwood and the ethanol oriental wormwood extract can effectively improve autoimmune hepatitis.

The present invention provides methods and materials for treating mammals (e.g., humans) that have or are at risk of developing a disease or condition characterized by tissue inflammation and / or degeneration. [Solution] For example, mesenchymal stem cells (MSCs) that express tissue-targeting antigen receptors (e.g., chimeric antigen receptors) capable of exerting immunosuppressive effects in targeted tissues are provided, as well as a method using such MSCs.

The invention discloses application of an iron chelating agent in treatment of HSV-1 and VSV virus infection. By constructing a mouse model infected by HSV-1 and VSV viruses, it is verified that the iron chelating agent can significantly promote activation of an I-type interferon signal channel of a host after virus infection; virus replication in various tissues can be inhibited, and secretion of antiviral cell factors can be promoted; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows a consistent immunopotentiation effect in mouse and human immune cells; the iron chelating agent is selected from any one or a combination of more of deferoxamine mesylate, deferiprone and ciclopirox. The iron chelating agent provided by the invention does not depend on virus TK / DNApol, overcomes the defect of high drug resistance of traditional HSV-1 and VSV virus treatment drugs to a certain extent, and has good clinical application prospects and application values.

1. The name of the design product: laser hair removal treatment head. 2. The use of the design product: laser through the hair removal treatment head on the skin, ease or eliminate the corresponding area of inflammation or discomfort of the organization. 3. The design points of the design product: in the front view. 4. The picture or photo that best indicates the design points: front view.